Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
about
An Overview of Current Regulatory Requirements for Approval of Biosimilar InsulinsPhysiology and pharmacology of erythropoietinUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.Biosimilars: Implications for health-system pharmacists.Erythropoietin after a century of research: younger than ever.Potential impact of subsequent entry biologics in nephrology practice in Canada.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.The protein science of biosimilars.Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production.Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.Clinical trials for authorized biosimilars in the European Union: a systematic review.Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Erythropoietin biosimilars currently available in hematology-oncology.Clinical safety of biosimilar recombinant human erythropoietins.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Clinical development of biosimilars: an evolving landscape.Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilar therapeutics-what do we need to consider?Biologicals and biosimilars: safety issues in Europe.Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Problems associated with current anti-doping testing: is quality assessment a reliable solution?Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
P2860
Q26823562-24143F18-4E7C-4803-8E93-F1CC0FBA4A38Q26866945-B63BA44F-7CE9-4596-8C89-DA9D802F3B8BQ34352446-FCC44B7A-F350-4E72-BE1E-4D37DB33876BQ34372394-7D77FC09-5A4D-48BF-8446-EEFC0EDB44BAQ34606348-8856FBE9-A38E-44D1-A595-F5C04BB69F1BQ35146196-04168BB4-DFE8-4D7A-9DDA-D548BF254668Q35162053-93048388-4070-4C31-8B2C-862E31300D25Q36588724-39FB3618-47AF-4683-904E-DAC72E059521Q36603218-0AE61A80-BF83-4CB3-ABC0-B5AD049D02DDQ36736105-4A6F9EF8-608A-49CE-888C-F12BAF963D17Q37023771-56C203D6-3A47-4083-9DB3-15C20E766E07Q37399588-71AF72B2-C90D-48BB-8CE8-51D38A0556EBQ37700537-D8CFC205-3959-4CB0-8EF4-060D3F661596Q37976605-2FFF290A-EB19-49C4-945B-81C1005E5DD9Q38033576-FD04359A-D708-4B41-8280-5F00F7E70834Q38075798-68C83F2B-330E-4D00-A2CD-C2ED5B76F078Q38083094-381F2604-B682-4142-B6C8-235A41B85608Q38150859-684F8711-BDE6-4E09-994E-18966818D4E3Q38556990-B8026175-8B9F-45B1-AE94-8AEB043AF19CQ38708927-A66FE5F5-A18A-4CB1-B8ED-5956EB5B7C2DQ41841849-8A2C4B66-E515-4763-B424-C2C59D3515E5Q48104740-18424884-C6C6-43D1-8BFB-ED03878B0990Q51782444-6B3F49C8-2E7E-4FC0-9903-9CF38D862799Q54959955-7EBAC7BC-F1A0-4767-BB97-305C8C0B16CE
P2860
Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@ast
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@en
type
label
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@ast
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@en
prefLabel
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@ast
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@en
P2093
P2860
P1433
P1476
Biosimilar epoetins: an analys ...... of biopharmaceutical proteins.
@en
P2093
Christian Combe
Huub Schellekens
Roger L Tredree
P2860
P304
P356
10.1592/PHCO.2005.25.7.954
P407
P577
2005-07-01T00:00:00Z